Infosys and ValGenesis partner to bring paperless validation to the pharmaceutical and biotech industry

Global software major **Infosys** said on 4 January that it has entered into a partnership with paperless validation company ValGenesis to enhance compliance and quality management for its customers in the healthcare and life sciences sectors. [caption id=“attachment_4240995” align=“alignleft” width=“380”]  Representational image. Reuters.[/caption] Under the partnership, Infosys will integrate ValGenesis’ “Validation Lifecycle Management System” (VLMS) within its suite of services for the pharmaceutical and biotech industry which will be delivered in secure Cloud environment, Infosys said in a statement. South San Francisco, California-headquartered ValGenesis is a major paperless validation life cycle management solution in the life sciences industry that allows customers to automate the validation process fully, eliminate inefficiencies found in paper-based manual processes, while also reducing costs and validation cycle times. The ValGenesis Validation Lifecycle Management System (VLMS) manages all types of validation activities such as equipment, computer systems, cleaning, analytical methods, and process validation. The system delivers technology solutions that are fully configurable and rapidly deployable onsite or by way of a secured Cloud environment. Through this partnership, Infosys said it would help biopharma and medical devices customers transform to next generation of automation driven quality and compliance services which will help organisations generate significant efficiencies and allow them to focus on their core business. “Healthcare is potentially the world’s most stringently-regulated industry. The huge volumes of highly-sensitive information that biotech and life sciences firms generate is subject to incredibly strict standards, for example, recording the outcomes from clinical trials,” said Sangita Singh, Executive Vice President and Head, Healthcare & Lifesciences, Infosys. “The **digitisation** of the industry to ensure better data and document accuracy is incredibly important for many ethical, legal and business reasons,” Singh added. In general, the validation systems are still almost entirely manual, paper-based process, resulting in significant inefficiencies, higher costs and more significant opportunity for errors to creep in. They can also result in delays to life-saving medicines and procedures to patients. “ValGenesis is pioneering paperless validation, and our new partnership will bring significant savings and much better compliance to our customers,” Singh said. ValGenesis’ VLMS includes a regulatory framework allowing validation requirements to be specified in advance. Leveraging its capabilities and experience in the life sciences space, Infosys plans to deliver VLMS to its customers as a single “paperless” system that manages every activity in the entire validation lifecycle.